Voyageur Pharmaceuticals Ltd. (VYYRF)
| Market Cap | 15.45M -7.6% |
| Revenue (ttm) | 8.36K |
| Net Income | -2.53M |
| EPS | -0.02 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,500 |
| Average Volume | 20,190 |
| Open | 0.0880 |
| Previous Close | 0.1080 |
| Day's Range | 0.0880 - 0.0880 |
| 52-Week Range | 0.0033 - 0.2500 |
| Beta | 0.16 |
| RSI | 36.09 |
| Earnings Date | Mar 27, 2026 |
About Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd., together with its subsidiaries, engages in acquiring, exploring, and developing raw materials for pharmaceutical products in the United States of America, the province of British Columbia, Canada, and the state of Utah. It develops barium and iodine-based APIs. The company offers Smooth HD, Smooth X, Smooth LD, Vision HD, Vision LD, V-Gas, and other products. The company has a collaboration with Bayer Aktiengesellschaft for the research and development of evaluating potential future production of iodine to be used... [Read more]
News
Voyageur Announces Non-Brokered Life Offering
Calgary, Alberta, Canada – March 25, 2026 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (the "Company" or "Voyageur"), a Canadian developer of pharmaceutical-grade barium and iodine for me...
Voyageur Announces Advancements on its Barium & Iodine Contrast Media Projects
Calgary, Alberta, Canada – TheNewswire – March 16, 2026 - Voyageur Pharmaceuticals Ltd . ( TSX-V: VM) (OTC Pink: VYYRF) (the "Company" or "Voyageur"), a pharmaceutical company focused on developing b...
Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant; Announces Stock Option and DSU grants, and Proposed Issuance of Securities for Debt
Purity Exceeding Pharmaceutical Grade, 98.8% BaSO4
Voyageur Pharmaceuticals Announces Collaboration with Bayer
Calgary, Alberta, Canada – TheNewswire – February 23, 2026 - Voyageur Pharmaceuticals Ltd. ( TSXV:VM) ( OTC Pink:VYYRF) (" Voyageur " or the " Company ") a Canadian developer of pharmaceutical-grade ...
Voyageur Pharmaceuticals Strengthens Scientific Team by Adding Dr. Brian Mueller as Director of Chemistry and Secures Exclusive Ownership of Iodine Extraction Technology
Calgary, Alberta, Canada – TheNewswire - January 12, 2026 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium ...
Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Seasoned Financial Executive Virginia Alling to Drive U.S. Market Expansion
Calgary, AB – November 7, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC: VYYRF) (the “Company” or “Voyageur”), a Canadian developer of pharmaceutical-grade barium and iodine for m...
Voyageur Pharmaceuticals Signs Non-Exclusive Distribution & Wholesale Agreement with PHALANX
Calgary, Alberta, Canada – October 29, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”), a Canadian public company developing cost-effective...
Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Wall Street Expertise to Facilitate U.S. Market Expansion
Calgary, AB – October 23, 2025 - TheNewswire – Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC: VYYRF), (the “Company” or “Voyageur”) a Canadian developer of pharmaceutical-grade barium and iodine for m...
Voyageur Pharmaceuticals Launches U.S. Iodine Feasibility Study to Establish First Fully Integrated North American Contrast Drug Manufacturing Platform
Calgary, Canada – TheNewswire – August 25, 2025 - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC: VYYRF) ("Voyageur" or the "Corporation") is pleased to announce the launch of its U.S.-based iodine fe...
Voyageur Pharmaceuticals Initiates First Commercial Shipments of Barium Contrast Products to Canadian Clinics
Calgary, Alberta, Canada – August 21, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company"), a radiology contrast media company focused on vertic...
Voyageur Pharmaceuticals Announces Exercise of Warrants for Gross Proceeds of $1.69 Million
Calgary, Alberta, Canada – TheNewswire - August 19, 2025 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“ Voyageur ” or the “ Company ”), a company with a strategic focus on vertically i...
Voyageur Advances Frances Creek Barite Project with VAST Engagement for Bulk Sample Permit
Calgary, Canada – TheNewswire – August 18, 2025 - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC: VYYRF) ("Voyageur" or the "Corporation"), is pleased to announce that it has engaged VAST Resource Sol...
Voyageur Pharmaceuticals Grants Deferred Share Units and Options and Accelerates Expiry Date of Warrants
Calgary, Canada – TheNewswire – July 14, 2025 - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC: VYYRF) ("Voyageur" or the "Corporation"), a provider of innovative medical imaging solutions, announces ...
Voyageur Pharmaceuticals Signs LOI for Latin America Distribution Partnership Supporting Global Market Expansion
Calgary, Alberta, Canada – TheNewswire - June 24, 2025 – Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“ Voyageur ”, or the “ Company ”), a Canadian public company developing cost-effecti...
Voyageur and Altillion Forge Landmark Alliance to Establish North America's First Vertically Integrated Iodine Drug Supply Chain
Calgary, Alberta – TheNewswire - June 23, 2025 – Voyageur Pharmaceuticals Ltd. (TSXV:VM) (“Voyageur” or the “Company”), a Canadian public company developing cost-effective imaging contrast media, is p...
Voyageur Enters Revenue Stage with First Commercial Sale of Barium Contrast Agents
Calgary, Alberta, Canada – TheNewswire - June 4, 2025 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company"), a radiology contrast media company focused on vertical ...
Voyageur Pharmaceuticals Announces Appointment of Ethan Mohan as Executive Vice President
Calgary, Alberta, Canada – May 12, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. ( TSX.V:VM) ( OTC Pink:VYYRF) (" Voyageur " or the " Company ") a radiology contrast media company focused on ve...
Voyageur Pharmaceuticals Announces Changes to Board of Directors and DSU Grant
FOR IMMEDIATE RELEASE Ralph Hesje Retires as Chairman
Voyageur Pharmaceuticals Grants Deferred Share Units
Calgary, Canada – TheNewswire – April 7, 2025 - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC: VYYRF) ("Voyageur" or the "Corporation"), a provider of innovative medical imaging solutions, announces ...
Voyageur Completes Human Testing of Barium Contrast Products and Prepares for Canadian Market Launch
Calgary, Alberta, Canada – April 1, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (" Voyageur " or the " Company ") is pleased to announce the successful completion of...
Voyageur Pharmaceuticals Advances Frances Creek Project, Paving the Way for a Secure, Vertically Integrated Barium Contrast Product Line
Calgary, Alberta, Canada – March 4, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“ Voyageur ” or the “ Company ”) is pleased to announce the commencement of the Fran...
Voyageur Clarifies Terms of Previously Announced Agreement
Calgary, Alberta--(Newsfile Corp. - March 3, 2025) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company") wishes to clarify the terms of a distribution and wholesal...
Voyageur Advances MRI Drug Development Using Next Generation Endohedral Fullerenes
Calgary, Alberta, Canada – February 18, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. ( TSX.V:VM) (OTC Pink:VYYRF) ("Voyageur" or the "Company") is pleased to announce the launch of its next gen...
Voyageur Receives $600K Grant from Alberta Innovates for Product Development
Voyageur receives $600,000 in funding through Alberta Innovates AICE-Market Access Program
Voyageur Announces Proposed Private Placement
Calgary, Alberta--(Newsfile Corp. - October 17, 2024) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Corporation"), is pleased to announce a proposed non-brokered pri...